A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma
The REGARD trial demonstrated that ramucirumab monotherapy improved both overall survival (OS) and progression-free survival (PFS) compared with best supportive care plus placebo as second-line treatment for patients with advanced gastric cancer. However, the efficacy and safety of ramucirumab monotherapy for previously treated Japanese patients with advanced gastric cancer remains unknown.
Previously treated Japanese patients with advanced gastric cancer who received ramucirumab monotherapy between June 2015 and March 2016 at the Cancer Institute Hospital were enrolled in the study. OS, PFS, best overall response, and safety profiles were retrospectively evaluated.
Nineteen patients were enrolled in this study. Ramucirumab monotherapy was generally administered as third-line therapy. After a median follow-up period of 7.4 months, the median PFS was 2.1 months (95% CI 1.0–3.5), and median OS was 12.9 months (95% CI 2.3, not reached). In 13 patients who had measurable lesions on radiologic examination, partial response was observed in one patient (7.7%) and stable disease was observed in five patients (38.5%). A total of 12 patients (63.2%) had adverse events (AEs). Common AEs included hypertension (8 patients, 42.1%), fatigue (6 patients, 31.6%), and bleeding (5 patients, 26.3%). Grade 3 AEs included gastrointestinal bleeding and aspiration pneumonia (1 patient each, 5.3%).
Our data suggest that ramucirumab monotherapy in Japanese patients with previously treated advanced gastric cancer has comparable efficacy and safety profiles as reported in the REGARD trial.
KeywordsRamucirumab Monotherapy Gastric Cancer Japanese
This work was funded by the research foundation of the JFCR.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
Research involving human participants and/or animals
Informed consent was obtained from all patients for inclusion in this study.
- 1.GLOBOCAN (2012) Cancer Incident and mortality worldwide: IARC cancer base no. 11 (Internet). http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
- 2.Center for Cancer Control and Information Services, National Cancer Center Japan (2016) Projected cancer statistics. http://ganjoho.jp/en/public/statistics/short_pred.html
- 12.Hironaka S, Ueda S, Yasui H et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31:4438–4444CrossRefPubMedGoogle Scholar
- 15.Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235CrossRefPubMedGoogle Scholar
- 17.Japanese Gastric Cancer Association (2017) Japanese gastric cancer treatment guideline 2014 (ver. 4). Gastric cancer. 2017; 20(1): 1−19Google Scholar
- 18.Wakatsuki T, Zhang W, Yang D et al. (2012) Ethnic gene profile of genes involved in angiogenesis to predict regional bevacizumab efficacy difference in gastric cancer. J Clin Oncol. 30; 15s: suppl abstr. 4026Google Scholar